| Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver P Dongiovanni, S Stender, A Pietrelli, RM Mancina, A Cespiati, S Petta, ... Journal of internal medicine 283 (4), 356-370, 2018 | 312 | 2018 |
| Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis S Pelusi, A Cespiati, R Rametta, G Pennisi, V Mannisto, C Rosso, ... Clinical Gastroenterology and Hepatology 17 (11), 2310-2319. e6, 2019 | 89 | 2019 |
| PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients P Dongiovanni, M Meroni, G Baselli, RM Mancina, M Ruscica, M Longo, ... Journal of lipid research 60 (6), 1144-1153, 2019 | 53 | 2019 |
| Rare ATG7 genetic variants predispose patients to severe fatty liver disease GA Baselli, O Jamialahmadi, S Pelusi, E Ciociola, F Malvestiti, M Saracino, ... Journal of Hepatology 77 (3), 596-606, 2022 | 46 | 2022 |
| Pain and frailty in hospitalized older adults I Ardoino, C Franchi, A Nobili, PM Mannucci, O Corli Pain and therapy 9, 727-740, 2020 | 30 | 2020 |
| Impact of sarcopenia and myosteatosis in non-cirrhotic stages of liver diseases: similarities and differences across aetiologies and possible therapeutic strategies A Cespiati, M Meroni, R Lombardi, G Oberti, P Dongiovanni, ... Biomedicines 10 (1), 182, 2022 | 19 | 2022 |
| Interaction between lifestyle changes and PNPLA3 genotype in NAFLD patients during the COVID-19 lockdown F Cinque, A Cespiati, R Lombardi, A Costantino, G Maffi, F Alletto, ... Nutrients 14 (3), 556, 2022 | 14 | 2022 |
| Genetics and epigenetics in the clinic: precision medicine in the management of fatty liver disease A Cespiati, NA Youngson, A Tourna, L Valenti Current Pharmaceutical Design 26 (10), 998-1009, 2020 | 14 | 2020 |
| Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity R Lombardi, VL Mura, A Cespiati, F Iuculano, G Sigon, G Pallini, M Proietti, ... Internal and emergency medicine 17 (6), 1739-1749, 2022 | 7 | 2022 |
| Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled … A Cespiati, S Petta, R Lombardi, V Di Marco, V Calvaruso, C Bertelli, ... Digestive and Liver Disease 53 (10), 1301-1307, 2021 | 7 | 2021 |
| Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD S Pelusi, L Ronzoni, J Rondena, C Rosso, G Pennisi, P Dongiovanni, ... Clinical Gastroenterology and Hepatology, 2024 | 4 | 2024 |
| An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians A Cespiati, F Cinque, M Meroni, R Lombardi, P Dongiovanni, ... Biomedicines 11 (2), 586, 2023 | 4 | 2023 |
| Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension F Cattazzo, R Lombardi, A Mantovani, M Bevilacqua, M Zoncapè, LI Prat, ... Nutrition, Metabolism and Cardiovascular Diseases 32 (12), 2839-2847, 2022 | 4 | 2022 |
| Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients F Carlotta, R Raffaella, A Ilaria, N Alessandro, MP Mannuccio, ... European Journal of Internal Medicine 68, e7-e11, 2019 | 4 | 2019 |
| Anemia management and transfusion strategy in internal medicine units: Less is more D Blanca, G Parrella, D Consonni, S Villa, G Ceriani, A Cespiati, G Figini, ... European Journal of Internal Medicine 115, 48-54, 2023 | 3 | 2023 |
| The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value E Paolini, M Longo, M Meroni, G Tria, A Cespiati, R Lombardi, S Badiali, ... Frontiers in Nutrition 10, 1101341, 2023 | 3 | 2023 |
| MAFLD and NAFLD: is there the need for redefining the risk of cardiovascular disease and mortality? R Lombardi, A Cespiati, P Francione, F Cinque, S Fargion, AL Fracanzani Metabolism Target Organ Damage 2, 12, 2022 | 3 | 2022 |
| Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors R Lombardi, A Mantovani, A Cespiati, P Francione, G Maffi, E Del Zanna, ... Digestive and Liver Disease 56 (4), 551-558, 2024 | 2 | 2024 |
| Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades R Lombardi, L Colavolpe, F Alletto, A Cespiati, E Fatta, C Bertelli, ... Digestive and Liver Disease 56 (1), 144-151, 2024 | 2 | 2024 |
| Nutritional and Lifestyle Therapy for NAFLD in People with HIV F Cinque, A Cespiati, R Lombardi, G Guaraldi, G Sebastiani Nutrients 15 (8), 1990, 2023 | 2 | 2023 |
